In:
Breast Cancer Research and Treatment, Springer Science and Business Media LLC, Vol. 187, No. 2 ( 2021-06), p. 603-603
Abstract:
In the original publication, two values provided for landmark survival for patients treated with gemcitabine were incorrectly listed in the text. On page 562, paragraph 3, the text listed that: “for TNBC: 50%, 31%, 20%, and 3%, respectively, for HR+/HER2−: 51%, 27%, 10%, and 3%, respectively”. The correct values should be “for TNBC: 50%, 31%, 11%, and 3%, respectively, for HR+/HER2−: 51%, 27%, 10%, and 7%, respectively”. The correct values are consistent with those listed in Table 2.
Type of Medium:
Online Resource
ISSN:
0167-6806
,
1573-7217
DOI:
10.1007/s10549-021-06223-6
Language:
English
Publisher:
Springer Science and Business Media LLC
Publication Date:
2021
detail.hit.zdb_id:
2004077-5
Bookmarklink